Literature DB >> 33203670

Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients.

Xiaoling Xu1, Mingfeng Han2, Tiantian Li3, Wei Sun2, Dongsheng Wang3, Binqing Fu4,5, Yonggang Zhou4,5, Xiaohu Zheng4,5, Yun Yang6, Xiuyong Li7, Xiaohua Zhang2, Aijun Pan6, Haiming Wei8,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33203670      PMCID： PMC7733842          DOI： 10.1073/pnas.2017204117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  11 in total

1.  Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.

Authors:  Savino Sciascia; Franco Aprà; Alessandra Baffa; Simone Baldovino; Daniela Boaro; Roberto Boero; Stefano Bonora; Andrea Calcagno; Irene Cecchi; Giacoma Cinnirella; Marcella Converso; Martina Cozzi; Paola Crosasso; Fabio De Iaco; Giovanni Di Perri; Mario Eandi; Roberta Fenoglio; Massimo Giusti; Daniele Imperiale; Gianlorenzo Imperiale; Sergio Livigni; Emilpaolo Manno; Carlo Massara; Valeria Milone; Giuseppe Natale; Mauro Navarra; Valentina Oddone; Sara Osella; Pavilio Piccioni; Massimo Radin; Dario Roccatello; Daniela Rossi
Journal:  Clin Exp Rheumatol       Date:  2020-05-01       Impact factor: 4.473

2.  Tocilizumab in patients with severe COVID-19: a retrospective cohort study.

Authors:  Giovanni Guaraldi; Marianna Meschiari; Alessandro Cozzi-Lepri; Jovana Milic; Roberto Tonelli; Marianna Menozzi; Erica Franceschini; Gianluca Cuomo; Gabriella Orlando; Vanni Borghi; Antonella Santoro; Margherita Di Gaetano; Cinzia Puzzolante; Federica Carli; Andrea Bedini; Luca Corradi; Riccardo Fantini; Ivana Castaniere; Luca Tabbì; Massimo Girardis; Sara Tedeschi; Maddalena Giannella; Michele Bartoletti; Renato Pascale; Giovanni Dolci; Lucio Brugioni; Antonello Pietrangelo; Andrea Cossarizza; Federico Pea; Enrico Clini; Carlo Salvarani; Marco Massari; Pier Luigi Viale; Cristina Mussini
Journal:  Lancet Rheumatol       Date:  2020-06-24

Review 3.  Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.

Authors:  Chelsea Kotch; David Barrett; David T Teachey
Journal:  Expert Rev Clin Immunol       Date:  2019-06-20       Impact factor: 4.473

4.  Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.

Authors:  Ruggero Capra; Nicola De Rossi; Flavia Mattioli; Giuseppe Romanelli; Cristina Scarpazza; Maria Pia Sormani; Stefania Cossi
Journal:  Eur J Intern Med       Date:  2020-05-13       Impact factor: 4.487

5.  Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.

Authors:  T Klopfenstein; S Zayet; A Lohse; J-C Balblanc; J Badie; P-Y Royer; L Toko; C Mezher; N J Kadiane-Oussou; M Bossert; A-M Bozgan; A Charpentier; M-F Roux; R Contreras; I Mazurier; P Dussert; V Gendrin; T Conrozier
Journal:  Med Mal Infect       Date:  2020-05-06       Impact factor: 2.152

6.  Effective treatment of severe COVID-19 patients with tocilizumab.

Authors:  Xiaoling Xu; Mingfeng Han; Tiantian Li; Wei Sun; Dongsheng Wang; Binqing Fu; Yonggang Zhou; Xiaohu Zheng; Yun Yang; Xiuyong Li; Xiaohua Zhang; Aijun Pan; Haiming Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

7.  Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.

Authors:  Christina C Price; Frederick L Altice; Yu Shyr; Alan Koff; Lauren Pischel; George Goshua; Marwan M Azar; Dayna Mcmanus; Sheau-Chiann Chen; Shana E Gleeson; Clemente J Britto; Veronica Azmy; Kelsey Kaman; David C Gaston; Matthew Davis; Trisha Burrello; Zachary Harris; Merceditas S Villanueva; Lydia Aoun-Barakat; Insoo Kang; Stuart Seropian; Geoffrey Chupp; Richard Bucala; Naftali Kaminski; Alfred I Lee; Patricia Mucci LoRusso; Jeffrey E Topal; Charles Dela Cruz; Maricar Malinis
Journal:  Chest       Date:  2020-06-15       Impact factor: 9.410

8.  Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm.

Authors:  Chuang Guo; Bin Li; Huan Ma; Xiaofang Wang; Pengfei Cai; Qiaoni Yu; Lin Zhu; Liying Jin; Chen Jiang; Jingwen Fang; Qian Liu; Dandan Zong; Wen Zhang; Yichen Lu; Kun Li; Xuyuan Gao; Binqing Fu; Lianxin Liu; Xiaoling Ma; Jianping Weng; Haiming Wei; Tengchuan Jin; Jun Lin; Kun Qu
Journal:  Nat Commun       Date:  2020-08-06       Impact factor: 14.919

9.  Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions?

Authors:  Yong Wang; Qing Mao; Xiangdong Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-17       Impact factor: 11.205

10.  Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.

Authors:  J Eimer; J Vesterbacka; A-K Svensson; B Stojanovic; C Wagrell; A Sönnerborg; P Nowak
Journal:  J Intern Med       Date:  2020-08-18       Impact factor: 13.068
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.